Table 3.
Clinical presentation at baseline, 3, 6 and 12 months
| Baseline | 3 months | 6 months | 12 months | |||||
|---|---|---|---|---|---|---|---|---|
| n = 111 | n = 106 | n = 100 | n = 85 | |||||
| Acanthosis nigricans present | 94 | (84.7) | 88 | (83.8)* | 79 | (85.9)† | 61 | (76.3)§ |
| Pre-diabetes | 14 | (12.6) | 19 | (17.9) | 10 | (12.1)†,** | ||
| Dyslipidaemia | 61 | (55.0)* | 57 | (54.3)* | 51 | (53.7)| | 32 | (28.8)† |
| (HDL-C <1.03 mmol/L and/or triglycerides ≥1.7 mmol/L) | ||||||||
| SBP and/or DBP ≥90 percentile | 49 | (44.1) | 41 | (38.7) | 30 | (30.6)† | 37 | (43.5) |
| Elevated liver enzymes (ALT and/or GGT ≥1.5 upper limit of 30 U/L) | 22 | (20.0)† | 21 | (20.4)‡ | 17 | (17.3)† | 14 | (12.6)‡ |
| Microalbuminuria | 9 | (8.5)§ | 9 | (8.9)§ | 9 | (9.5)§ | 9§ | (8.1)§ |
| (Urine/albumin/creatinine, Girls: 3.5 to 25 mg/mmol, Boys: 2.5 to 25 mg/mmol) | ||||||||
*1 missing value, †2 missing values, ‡3 missing values, §5 missing values, | 8 missing values **including one adolescent diagnosed with type 2 diabetes.
Values are n (%).